225 related articles for article (PubMed ID: 35355169)
1. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.
Bayraktar Bilen N; Bilen Ş; Topçu Yılmaz P; Evren Kemer Ö
Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the topographical measurements and tear function status in patients with hemifacial spasm: A comparative fellow eye study.
Bayraktar Bilen N; Bilen S
Eur J Ophthalmol; 2023 Jan; 33(1):216-222. PubMed ID: 35787190
[TBL] [Abstract][Full Text] [Related]
3. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
[TBL] [Abstract][Full Text] [Related]
4. Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study.
Pellegrini M; Schiavi C; Taroni L; Sebastiani S; Bernabei F; Roda M; Moscardelli F; Giannaccare G
Indian J Ophthalmol; 2019 Sep; 67(9):1405-1409. PubMed ID: 31436182
[TBL] [Abstract][Full Text] [Related]
5. Influence of involuntary eyelid spasms on corneal topographic and eyelid morphometric changes in patients with hemifacial spasm.
Osaki T; Osaki MH; Osaki TH; Hirai FE; Nallasamy N; Campos M
Br J Ophthalmol; 2016 Jul; 100(7):963-970. PubMed ID: 26541432
[TBL] [Abstract][Full Text] [Related]
6. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
[TBL] [Abstract][Full Text] [Related]
7. Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A.
Jariyakosol S; Uthaithammarat L; Chatwichaikul N; Kasetsuwan N; Chongpison Y
Clin Ophthalmol; 2021; 15():1775-1782. PubMed ID: 33953536
[TBL] [Abstract][Full Text] [Related]
8. Differences in Corneal Parameters Between Affected and Normal Contralateral Eyes in Patients With Hemifacial Spasm Treated With Botulinum Toxin-A: Outcomes During One Complete Treatment Cycle.
Osaki T; Osaki MH; Osaki TH; Hirai FE; Campos M
Cornea; 2016 Feb; 35(2):220-5. PubMed ID: 26619386
[TBL] [Abstract][Full Text] [Related]
9. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
Ho RW; Fang PC; Chao TL; Chien CC; Kuo MT
Sci Rep; 2018 May; 8(1):8367. PubMed ID: 29849166
[TBL] [Abstract][Full Text] [Related]
10. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
Lu R; Huang R; Li K; Zhang X; Yang H; Quan Y; Li Q
Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
[TBL] [Abstract][Full Text] [Related]
11. Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB.
Isshiki Y; Ishikawa H; Mimura O
Jpn J Ophthalmol; 2016 Nov; 60(6):486-491. PubMed ID: 27503401
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
Hosotani Y; Yokoi N; Okamoto M; Ishikawa H; Komuro A; Kato H; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
[TBL] [Abstract][Full Text] [Related]
13. Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines.
Choi MG; Yeo JH; Kang JW; Chun YS; Lee JK; Kim JC
Graefes Arch Clin Exp Ophthalmol; 2019 Feb; 257(2):331-338. PubMed ID: 30552510
[TBL] [Abstract][Full Text] [Related]
14. [Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
Oliveira FC; Oliveira GC; Cariello AJ; Felberg S; Osaki MH
Arq Bras Oftalmol; 2010; 73(5):405-8. PubMed ID: 21225122
[TBL] [Abstract][Full Text] [Related]
15. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
Park DI; Shin HM; Lee SY; Lew H
Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
[TBL] [Abstract][Full Text] [Related]
16. Relations between nonmotor manifestations and motor disorders in patients with benign essential blepharospasm.
Zhou Y; Wang W; Lin Z; Lin T; Gong L
Graefes Arch Clin Exp Ophthalmol; 2023 Dec; 261(12):3615-3623. PubMed ID: 37341835
[TBL] [Abstract][Full Text] [Related]
17. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection.
Kocabeyoglu S; Sekeroglu HT; Mocan MC; Muz E; Irkec M; Sanac AS
Eur J Ophthalmol; 2014; 24(6):830-4. PubMed ID: 24803156
[TBL] [Abstract][Full Text] [Related]
18. [Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
Yabiku MM; Sartori Jde F; Sarraff EP; Osaki TH; Hossaka SK; Pereira CI; Freitas Wd; Osaki MH; Cariello AJ
Arq Bras Oftalmol; 2011; 74(6):414-6. PubMed ID: 22331113
[TBL] [Abstract][Full Text] [Related]
19. Ocular Surface Metrics in Blepharospasm Patients After Treatment With Botulinum Toxin Injections.
Yabumoto C; Osaki MH; Osaki T; Gameiro GR; Campos M; Osaki TH
Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):475-478. PubMed ID: 36928309
[TBL] [Abstract][Full Text] [Related]
20. Lid wiper epitheliopathy in patients with blepharospasm and/or hemifacial spasm.
Romero-Caballero MD; Salmerón Ato MP; Palazón-Cabanes A; Caravaca-Alegría A
Arch Soc Esp Oftalmol (Engl Ed); 2022 Jul; 97(7):376-380. PubMed ID: 35292220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
